Relabáló/refrakter Hodgkin-lymphoma brentuximab vedotin kezelése: Hazai tapasztalatok

Translated title of the contribution: Brentuximab vedotin treatment in patients with relapsed or refractory hodgkin lymphoma: A hungarian retrospective study

Molnár Zsuzsa, Pinczés László Imre, Piukovics Klára, Istenes Ildikó, Wolf Krisztina, Csukly Zoltán, Szomor Árpád, A. Illés, Miltényi Zsófia

Research output: Contribution to journalArticle

Abstract

Introduction: The treatment of relapsed or refractory Hodgkin lymphoma is still a major therapeutic challenge. The use of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, represents a promising approach for these patients, however clinical outcomes have not yet been evaluated in Hungary. Aim: Our aim was to assess the efficacy, safety and outcome of brentuximab vedotin treatment in Hungarian Hodgkin lymphoma patients. Method: In this retrospective case note review we enrolled patients at 6 clinical sites countrywide who were diagnosed with Hodgkin lymphoma and received brentuximab vedotin between 1 January 2013 and 31 December 2016. Results: A total of 86 patients were treated with brentuximab vedotin during the examined period. Before therapy initiation 66% of our patients had advanced-stage disease. Overall response rate to brentuximab vedotin, administered before autologous hematopoietic stem cell transplantation (n = 54) was 66.6%, complete remission rate was 42.6%. Thirty patients received brentuximab vedotin after AHSCT, 46.67% responded to treatment, 30% achieved complete remission. Thirty-six patients received the drug as a single-agent therapy, 50 patients were given brentuximab vedotin in combination, 39 of them with bendamustin. Toxicity was observed only in 13.95% of our patients, most common symptom was skin rash. Based on our analysis the estimated 5-year overall survival rate was 78.7%, the estimated progression free survival rate was 23.59 months (95% CI: 19.50-27.68). Conclusion: Brentuximab vedotin carries a substantial improvement in the treatment of relapsed or refractory Hodgkin lymphoma. Our results underline prior observations published in the literature. The use of brentuximab vedotin in combination can be beneficial, however further investigation is needed on the subject.

Translated title of the contributionBrentuximab vedotin treatment in patients with relapsed or refractory hodgkin lymphoma: A hungarian retrospective study
Original languageHungarian
Pages (from-to)1630-1634
Number of pages5
JournalOrvosi Hetilap
Volume158
Issue number41
DOIs
Publication statusPublished - Oct 1 2017

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Brentuximab vedotin treatment in patients with relapsed or refractory hodgkin lymphoma: A hungarian retrospective study'. Together they form a unique fingerprint.

  • Cite this

    Zsuzsa, M., Imre, P. L., Klára, P., Ildikó, I., Krisztina, W., Zoltán, C., Árpád, S., Illés, A., & Zsófia, M. (2017). Relabáló/refrakter Hodgkin-lymphoma brentuximab vedotin kezelése: Hazai tapasztalatok. Orvosi Hetilap, 158(41), 1630-1634. https://doi.org/10.1556/650.2017.30867